ZNF503 combined with GATA3 is a prognostic factor in triple-negative breast cancer

References

• Albergaria, A., et al., 2009. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast cancer research : BCR, 11 (3), R40.
   PubMed Web of Science ®Google Scholar
• Asselin-Labat, M.L., et al., 2007. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature cell biology, 9 (2), 201–209.
   PubMed Web of Science ®Google Scholar
• Barzaman, K., et al., 2020. Breast cancer: Biology, biomarkers, and treatments. International immunopharmacology, 84, 106535.
   PubMed Web of Science ®Google Scholar
• Byrne, D.J., et al., 2017. GATA3 expression in triple-negative breast cancers. Histopathology, 71 (1), 63–71.
   PubMed Web of Science ®Google Scholar
• Cakir, A., et al., 2017. GATA3 expression and its relationship with clinicopathological parameters in invasive breast carcinomas. Pathology, research and practice, 213 (3), 227–234.
   PubMed Web of Science ®Google Scholar
• Cimino-Mathews, A., et al., 2013. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Human pathology, 44 (7), 1341–1349.
   PubMed Web of Science ®Google Scholar
• Ciocca, V., et al., 2009. The significance of GATA3 expression in breast cancer: a 10-year follow-up study. Human pathology, 40 (4), 489–495.
   PubMed Web of Science ®Google Scholar
• Curigliano, G., et al., 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of oncology, 28 (8), 1700–1712.
   PubMed Web of Science ®Google Scholar
• El-Arabey, A.A., and Abdalla, M., 2022. The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer. Human cell, 35 (4), 1298–1300.
   PubMed Web of Science ®Google Scholar
• Gown, A.M., Fulton, R.S., and Kandalaft, P.L., 2016. Markers of metastatic carcinoma of breast origin. Histopathology, 68 (1), 86–95.
   PubMed Web of Science ®Google Scholar
• Gulbahce, H.E., et al., 2013. Significance of GATA-3 expression in outcomes of patients with breast cancer who received systemic chemotherapy and/or hormonal therapy and clinicopathologic features of GATA-3-positive tumors. Human pathology, 44 (11), 2427–2431.
   PubMed Web of Science ®Google Scholar
• Guo, Z., et al., 2021. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2. Oncology reports, 45 (2), 523–534.
   PubMed Web of Science ®Google Scholar
• Husni Cangara, M., et al., 2021. Gata-3 and KI-67 expression in correlation with molecular subtypes of breast cancer. Breast disease, 40 (S1), S27–S31.
   PubMedGoogle Scholar
• Jansen, M.P., et al., 2007. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. Journal of clinical oncology : official journal of the American society of clinical oncology, 25 (6), 662–668.
   PubMed Web of Science ®Google Scholar
• Kong, S.Y., et al., 2016. The ELK3-GATA3 axis orchestrates invasion and metastasis of breast cancer cells in vitro and in vivo. Oncotarget, 7 (40), 65137–65146.
   PubMedGoogle Scholar
• Kouros-Mehr, H., et al., 2006. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell, 127 (5), 1041–1055.
   PubMed Web of Science ®Google Scholar
• Lal, S., et al., 2017. Molecular signatures in breast cancer. Methods (san diego, calif.), 131, 135–146.
   PubMed Web of Science ®Google Scholar
• Lin, H.Y., et al., 2017. GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer: database mining for GATA family members in malignancies. Oncotarget, 8 (21), 34750–34761.
   PubMedGoogle Scholar
• Liu, H., et al., 2014. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas. American journal of clinical pathology, 141 (5), 648–655.
   PubMed Web of Science ®Google Scholar
• Liu, J., et al., 2016. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. Cancer letters, 376 (1), 104–109.
   PubMed Web of Science ®Google Scholar
• Lu, G., and Zhang, Y., 2019. MicroRNA-340-5p suppresses non-small cell lung cancer cell growth and metastasis by targeting ZNF503. Cellular & molecular biology letters, 24, 34.
   PubMed Web of Science ®Google Scholar
• Lu, S., et al., 2019. Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance. BMC cancer, 19 (1), 1085.
   PubMed Web of Science ®Google Scholar
• Ma, X.J., et al., 2004. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer cell, 5 (6), 607–616.
   PubMed Web of Science ®Google Scholar
• Matthew, K., et al., 2019. Making a Tissue Microarray. Methods in molecular biology, 1897, 313–323.
   Google Scholar
• Nakamura, M., Runko, A.P., and Sagerström, C.G., 2004. A novel subfamily of zinc finger genes involved in embryonic development. Journal of cellular biochemistry, 93 (5), 887–895.
   PubMed Web of Science ®Google Scholar
• Paik, S., et al., 2004. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England journal of medicine, 351 (27), 2817–2826.
   PubMed Web of Science ®Google Scholar
• Pareja, F., et al., 2016. Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ breast cancer, 2, 16036.
   PubMed Web of Science ®Google Scholar
• Parikh, P., et al., 2005. GATA-3 expression as a predictor of hormone response in breast cancer. Journal of the American college of surgeons, 200 (5), 705–710.
   PubMed Web of Science ®Google Scholar
• Petrelli, F., et al., 2015. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast cancer research and treatment, 153 (3), 477–491.
   PubMed Web of Science ®Google Scholar
• Qi, G., and Li, L., 2020. LncRNA TTN-AS1 Promotes Progression of Non-Small Cell Lung Cancer via Regulating miR-491-5p/ZNF503 Axis. OncoTargets and therapy, 13, 6361–6371.
   PubMedGoogle Scholar
• Querzoli, P., et al., 2021. GATA3 as an Adjunct Prognostic Factor in Breast Cancer Patients with Less Aggressive Disease: A Study with a Review of the Literature. Diagnostics (diagnostics), 11 (4), 604.
   Web of Science ®Google Scholar
• Reid, S., et al., 2021. Impact of molecular subtype and race on HR+, HER2- breast cancer survival. Breast cancer research and treatment, 189 (3), 845–852.
   PubMed Web of Science ®Google Scholar
• Rizzo, A., et al., 2022a. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential. Expert opinion on investigational drugs, 31 (6), 495–498.
   PubMed Web of Science ®Google Scholar
• Rizzo, A., and Ricci, A.D., 2022. Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond. Expert opinion on investigational drugs, 31 (6), 549–555.
   PubMed Web of Science ®Google Scholar
• Rizzo, A., et al., 2022b. Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert opinion on investigational drugs, 31 (6), 557–565.
   PubMed Web of Science ®Google Scholar
• Shahi, P., et al., 2015. The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion. The journal of biological chemistry, 290 (6), 3803–3813.
   PubMed Web of Science ®Google Scholar
• Shahi, P., et al., 2017. ZNF503/Zpo2 drives aggressive breast cancer progression by down-regulation of GATA3 expression. Proceedings of the national academy of sciences of the united states of america, 114 (12), 3169–3174.
   PubMed Web of Science ®Google Scholar
• Sung, H., et al., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71 (3), 209–249.
   PubMed Web of Science ®Google Scholar
• Taneja, P., et al., 2010. Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clinical medicine insights. Oncology, 4, 15–34.
   PubMedGoogle Scholar
• Usary, J., et al., 2004. Mutation of GATA3 in human breast tumors. Oncogene, 23 (46), 7669–7678.
   PubMed Web of Science ®Google Scholar
• Viscardi, G., et al., 2022. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. European journal of cancer (oxford, England : 1990), 177, 175–185.
   PubMed Web of Science ®Google Scholar
• Voduc, D., Cheang, M., and Nielsen, T., 2008. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer epidemiology, biomarkers & prevention : a publication of the American association for cancer research, cosponsored by the American society of preventive oncology, 17 (2), 365–373.
   PubMed Web of Science ®Google Scholar
• Waks, A.G., and Winer, E.P., 2019. Breast Cancer Treatment: A Review. JAMA, 321 (3), 288–300.
   PubMed Web of Science ®Google Scholar
• Wang, H., et al., 2021. miR-325-3p Promotes the Proliferation, Invasion, and EMT of Breast Cancer Cells by Directly Targeting S100A2. Oncology research, 28 (7), 731–744.
   PubMed Web of Science ®Google Scholar
• Yeo, B., et al., 2015. Clinical utility of the IHC4 + C score in oestrogen receptor-positive early breast cancer: a prospective decision impact study. British journal of cancer, 113 (3), 390–395.
   PubMed Web of Science ®Google Scholar
• Yin, G., et al., 2019. ZNF503 accelerates aggressiveness of hepatocellular carcinoma cells by down-regulation of GATA3 expression and regulated by microRNA-495. Am J transl res, 11 (6), 3426–3437.
   PubMed Web of Science ®Google Scholar
• Yin, L., et al., 2020. Triple-negative breast cancer molecular subtyping and treatment progress. Breast cancer research : BCR, 22 (1), 61.
   PubMed Web of Science ®Google Scholar
• Yoon, N.K., et al., 2010. Higher levels of GATA3 predict better survival in women with breast cancer. Human pathology, 41 (12), 1794–1801.
   PubMed Web of Science ®Google Scholar
• Zhao, S., et al., 2020. Molecular subtypes and precision treatment of triple-negative breast cancer. Annals of translational medicine, 8 (7), 499.
   PubMed Web of Science ®Google Scholar